drug · antibody

HUMIRA

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

targets

Tumor necrosis factor

all catalysts(0)

nothing on the calendar yet

Trials studying HUMIRA

phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumabrecruitingn=40
phase1A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjectscompletedn=444
phase4A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasisrecruitingn=30
phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Diseaserecruitingn=100
phase3A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitisactive not recruitingn=30
phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasiscompletedn=478
phase4A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasisnot yet recruitingn=30
phase3A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritisactive not recruitingn=101

more trials →

News(4)

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 1d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 1mo ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
biopharma_dive · 1mo ago

brand

HUMIRA

trade names

Amgevita, Amsparity, Cyltezo, Halimatoz, Hefiya, Hulio

generic

ADALIMUMAB

MOA

12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 X 10 -10 M).

indication

1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HU

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 43m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

HUMIRA

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

targets

Tumor necrosis factor

all catalysts(0)

nothing on the calendar yet

Trials studying HUMIRA

more trials →

News(4)

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 1d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 1mo ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
biopharma_dive · 1mo ago

brand

HUMIRA

trade names

Amgevita, Amsparity, Cyltezo, Halimatoz, Hefiya, Hulio

generic

ADALIMUMAB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 43m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

HUMIRA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying HUMIRA

News(4)

Report a data issue

comments(0)

HUMIRA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying HUMIRA

News(4)

Report a data issue

comments(0)